NLRP3 and Parkinson disease: VTX3232 is another novel oral selective inhibitor of NLRP3 developed by Ventyx Biosciences that can cross the blood‒brain barrier for the treatment of neurodegenerative diseases, including Parkinson’s disease, multiple sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis.